Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Non-Current Liabilities: 2021-2023

Historic Total Non-Current Liabilities for Arcturus Therapeutics Holdings (ARCT) over the last 2 years, with Dec 2023 value amounting to $150.4 million.

  • Arcturus Therapeutics Holdings' Total Non-Current Liabilities fell 15.16% to $150.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $150.4 million, marking a year-over-year decrease of 15.16%. This contributed to the annual value of $150.4 million for FY2023, which is 15.16% down from last year.
  • Arcturus Therapeutics Holdings' Total Non-Current Liabilities amounted to $150.4 million in Q4 2023, which was down 14.85% from $176.6 million recorded in Q3 2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Total Non-Current Liabilities ranged from a high of $177.3 million in Q4 2022 and a low of $128.5 million during Q1 2021.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median Total Non-Current Liabilities value was $144.3 million (recorded in 2022), while the average stood at $153.0 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Total Non-Current Liabilities declined by 17.09% in 2022, and later increased by 22.41% in 2023.
  • Arcturus Therapeutics Holdings' Total Non-Current Liabilities (Quarterly) stood at $174.0 million in 2021, then fell by 17.09% to $177.3 million in 2022, then declined by 15.16% to $150.4 million in 2023.
  • Its last three reported values are $150.4 million in Q4 2023, $176.6 million for Q3 2023, and $144.2 million during Q2 2023.